For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
As of close of business last night, Tarsus Pharmaceuticals Inc’s stock clocked out at $41.16, down -0.31% from its previous closing price of $41.29. In other words, the price has decreased by -$0.31 from its previous closing price. On the day, 0.54 million shares were traded. TARS stock price reached its highest trading level at $41.7 during the session, while it also had its lowest trading level at $40.69.
Ratios:
To gain a deeper understanding of TARS’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.54 and its Current Ratio is at 5.57. In the meantime, Its Debt-to-Equity ratio is 0.21 whereas as Long-Term Debt/Eq ratio is at 0.21.
On November 20, 2023, Goldman started tracking the stock assigning a Neutral rating and target price of $19.Goldman initiated its Neutral rating on November 20, 2023, with a $19 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jun 17 ’25 when Farrow Jeffrey S sold 13,608 shares for $40.42 per share. The transaction valued at 550,035 led to the insider holds 36,704 shares of the business.
Farrow Jeffrey S bought 13,608 shares of TARS for $550,088 on Jun 17 ’25. On Jun 16 ’25, another insider, Lin Elizabeth Yeu, who serves as the Chief Medical Officer of the company, sold 1,006 shares for $41.08 each. As a result, the insider received 41,326 and left with 7,694 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TARS now has a Market Capitalization of 1729304448 and an Enterprise Value of 1366448768. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.40 while its Price-to-Book (P/B) ratio in mrq is 5.05. Its current Enterprise Value per Revenue stands at 5.848 whereas that against EBITDA is -12.682.
Stock Price History:
The Beta on a monthly basis for TARS is 0.80, which has changed by 0.39857292 over the last 52 weeks, in comparison to a change of 0.11844492 over the same period for the S&P500. Over the past 52 weeks, TARS has reached a high of $57.28, while it has fallen to a 52-week low of $20.08. The 50-Day Moving Average of the stock is -4.47%, while the 200-Day Moving Average is calculated to be -10.31%.
Shares Statistics:
It appears that TARS traded 643.39K shares on average per day over the past three months and 571580 shares per day over the past ten days. A total of 42.00M shares are outstanding, with a floating share count of 36.24M. Insiders hold about 13.75% of the company’s shares, while institutions hold 99.97% stake in the company. Shares short for TARS as of 1749772800 were 8111634 with a Short Ratio of 12.61, compared to 1747267200 on 7779546. Therefore, it implies a Short% of Shares Outstanding of 8111634 and a Short% of Float of 19.97.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Currently, 1.0 analysts are dedicated to thoroughly evaluating and rating the performance of Tarsus Pharmaceuticals Inc (TARS) in the stock market.The consensus estimate for the next quarter is -$0.35, with high estimates of -$0.35 and low estimates of -$0.35.
Analysts are recommending an EPS of between -$0.87 and -$1.6 for the fiscal current year, implying an average EPS of -$1.24. EPS for the following year is -$0.43, with 2.0 analysts recommending between $1.24 and -$2.1.
Revenue Estimates
In the current quarter, 5 analysts expect revenue to total $95.81M. It ranges from a high estimate of $103.93M to a low estimate of $87.73M. As of the current estimate, Tarsus Pharmaceuticals Inc’s year-ago sales were $40.81MFor the next quarter, 5 analysts are estimating revenue of $104.02M. There is a high estimate of $110.12M for the next quarter, whereas the lowest estimate is $92.87M.
A total of 7 analysts have provided revenue estimates for TARS’s current fiscal year. The highest revenue estimate was $430.69M, while the lowest revenue estimate was $359.25M, resulting in an average revenue estimate of $399.84M. In the same quarter a year ago, actual revenue was $182.95MBased on 6 analysts’ estimates, the company’s revenue will be $576.39M in the next fiscal year. The high estimate is $711.43M and the low estimate is $424.92M.
